IBB iShares Biotechnology ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 200.48 | Day Range | 200.53 – 206.85 |
| 52-Week Range | 149.09 – 217.12 | Volume | 2.46M |
| Avg Volume | 1.61M | AUM | $10.28B (Oct 10, 2026) |
| Expense Ratio | 0.44% | Yield (TTM) | 0.16% |
| NAV | 200.76 | Premium/Discount | +2.85% indicative |
| Inception | Feb 05, 2001 | Holdings | 243 |
| Issuer | iShares | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 464287556 | ISIN | US4642875565 |
| Management | Not stated in source data | ||
About this ETF
The iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +0.49% | +7.51% | +21.92% | +22.35% | +35.80% | +18.85% | +5.89% | +8.39% | +7.22% |
| Total return | +0.49% | +7.51% | +21.93% | +22.45% | +36.07% | +19.14% | +6.16% | +8.67% | +7.41% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.44% | Annual cost of a $10,000 investment | $44.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 246 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES | GILD | 8.37% | 5.99M | $880.7M |
| 2 | AMGEN INC | AMGN | 7.89% | 2.04M | $829.9M |
| 3 | VERTEX PHARMACEUTICALS | VRTX | 7.69% | 1.61M | $809.4M |
| 4 | REGENERON PHARMACEUTICALS | REGN | 5.40% | 768.03K | $568.0M |
| 5 | MODERNA | MRNA | 5.30% | 2.83M | $557.7M |
| 6 | NATERA | NTRA | 3.88% | 1.04M | $407.7M |
| 7 | ARGENX SE ADR | ARGX | 3.35% | 430.72K | $352.6M |
| 8 | ILLUMINA INC | ILMN | 2.94% | 1.17M | $308.8M |
| 9 | REVOLUTION MEDICINES | RVMD | 2.67% | 1.49M | $281.1M |
| 10 | BIOGEN | BIIB | 2.36% | 1.14M | $248.2M |
| 11 | ALNYLAM PHARMACEUTICALS | ALNY | 2.21% | 1.03M | $232.1M |
| 12 | BEONE MEDICINES AG | ONC | 2.17% | 652.02K | $228.3M |
| 13 | INCYTE CORP | INCY | 1.67% | 1.56M | $175.6M |
| 14 | UNITED THERAPEUTICS | UTHR | 1.63% | 321.29K | $171.2M |
| 15 | INSMED | INSM | 1.59% | 1.67M | $167.5M |
| 16 | GENMAB SPONSORED ADR | GMAB | 1.47% | 4.29M | $154.8M |
| 17 | ROIVANT SCIENCES LTD | ROIV | 1.32% | 4.06M | $139.0M |
| 18 | NEUROCRINE BIOSCIENCES | NBIX | 1.05% | 778.83K | $110.0M |
| 19 | EXELIXIS INC | EXEL | 1.04% | 1.86M | $109.7M |
| 20 | CHARLES RIVER LABORATORIES INTERNA | CRL | 1.04% | 365.89K | $109.0M |
| 21 | ASCENDIS PHARMA | ASND | 1.01% | 477.86K | $106.4M |
| 22 | MEDPACE HOLDINGS | MEDP | 1.00% | 174.16K | $105.0M |
| 23 | HALOZYME THERAPEUTICS | HALO | 0.91% | 870.26K | $95.6M |
| 24 | BRIDGEBIO PHARMA | BBIO | 0.84% | 1.36M | $88.3M |
| 25 | BIO TECHNE | TECH | 0.83% | 1.21M | $87.6M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.16% | Paid (last 12 months) | $0.3399 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 15, 2026 | Last payment | $0.0112 (Sep 18, 2026) |
| Growth 1Y | +27.60% | Growth 3Y / 5Y (ann.) | +1.51% / -0.20% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 15, 2026 | Sep 15, 2026 | Sep 18, 2026 | $0.0112 |
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.0238 |
| Mar 17, 2026 | Mar 17, 2026 | Mar 20, 2026 | $0.1218 |
| Dec 16, 2025 | Dec 16, 2025 | Dec 19, 2025 | $0.1831 |
| Sep 16, 2025 | Sep 16, 2025 | Sep 19, 2025 | $0.0828 |
| Mar 18, 2025 | Mar 18, 2025 | Mar 21, 2025 | $0.1212 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 20, 2024 | $0.0624 |
| Sep 25, 2024 | Sep 25, 2024 | Sep 30, 2024 | $0.2005 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 27, 2024 | $0.1260 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.1240 |
| Sep 26, 2023 | Sep 27, 2023 | Oct 02, 2023 | $0.1532 |
| Jun 07, 2023 | Jun 08, 2023 | Jun 13, 2023 | $0.0062 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 22.17% / 21.27% | Sharpe 1Y / 3Y | 1.70 / 0.834 |
| Max drawdown 1Y / 3Y | -9.63% / -24.85% | Sortino 1Y | 2.71 |
| Beta vs S&P 500 (3Y) | 0.806 | Correlation vs S&P 500 (1Y) | 0.446 |
| Downside deviation 1Y | 13.88% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 2.46M | Average volume | 1.61M |
| AUM | $10.28B | Premium/Discount | +2.85% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$135.4M | -1.30% | $10.41B → $10.28B |
| 1 Month | -$197.0M | -1.91% | $10.30B → $10.28B |
| 1 Week | -$456.3M | -4.28% | $10.67B → $10.28B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for IBB
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.